Sagimet Biosciences Inc. Series A (SGMT)
SGMT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/0001558370-25-002747-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SGMT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001400118 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$27.9M |
| Operating income | -$30.7M |
| Net margin | -1393.8% |
| Operating margin | -1537.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $75.1M |
| Total assets | $96.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 361.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $111.0M cash; operating cash flow -$10.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 71,367,877 (2026-11-05); 21,375,402 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-10-01 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$19.1M | -$12.1M | $111.0M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$14.0M | -$11.1M | $165.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$10.7M | -$8.6M | $36.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$9.6M | -$11.8M | $35.0M | No debt tags | Needs four quarters | 10-K 2026-03-11 |
| Q3 2025 2025-09-30 | Not filed | -$12.9M | -$10.2M | $32.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$10.4M | -$9.1M | $42.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$18.2M | -$14.5M | $64.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$16.2M | -$11.0M | $75.8M | No debt tags | Needs four quarters | 10-K 2026-03-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-01 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.8% |
| 1 month | +28.1% |
| 3 months | +10.1% |
| Year to date | +72.6% |
| 1 year | +32.0% |
| From 52-week high | -10.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OBX | Obsidian Therapeutics Inc. | $12.36 | -1.59% | $763.5M |
| ANNX | Annexon Inc. | $3.57 | -8.93% | $681.0M |
| APMD | Apnimed Inc. | $16.28 | -3.78% | $677.7M |
| ARDX | Ardelyx Inc. | $3.07 | -0.65% | $771.7M |
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| JANX | Janux Therapeutics Inc. | $10.92 | -3.96% | $668.1M |
| ALMS | Alumis Inc. | $5.14 | -8.21% | $667.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier